Nature as a remarkable chemist: a personal story of the discovery and development of Taxol
- PMID: 24413390
- PMCID: PMC3980006
- DOI: 10.1097/CAD.0000000000000063
Nature as a remarkable chemist: a personal story of the discovery and development of Taxol
Abstract
The development of a new anticancer drug with a novel structure and unique mechanism of action is an important event, especially when the drug plays a clear role in improving the outcome for cancer patients. No drug fits this description better than Taxol. However, during the early phases of its development, there was little interest in the drug, particularly in the medical community. The story of Taxol is long and fascinating, and includes many examples in which the drug could have been dropped, resulting in its antitumor activity never being available to patients. It was 21 years between the original landmark paper on the isolation and structural determination of Taxol and its approval in 1992 by the FDA for its use in the treatment of ovarian cancer.
Figures
References
-
- Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant Antitumor agents. VI. The isolation and structure of Taxol®, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93:2325–2327. - PubMed
-
- Persinous GJ, editor. Washington Insight. Sep 15, 1990.
-
- Wall ME, Wani MC, Cook CE, Palmer KH, McPhail HT, Sim GA. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc. 1966;88:3888–3890.
-
- Horwitz MS, Horwitz SB. Intracellular degradation of HeLa and adenovirus type 2 DNA induced by camptothecin. Biochem Biophys Res Commun. 1971;45(3):723–7. - PubMed
-
- Loike JD, Horwitz SB. Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells. Biochemistry. 1976;15(25):5443–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
